CSE: VPH | OTCQB: VPHIF | FSE: VP2
Valeo Pharma (CSE:VPH) is a Canadian pharmaceutical company focused on four therapeutic areas: Respiratory, Neurology, Oncology and Specialty Products. Within these areas Valeo now has 8 marketed brands and 4 additional products contributing to significant growth for the coming year.
Investor Relation Contact
Director Communications & Investor Relations
16667, Hymus Boul.
1 (416) 361-9080
Research Capital Corporation
1 (416) 860-8675
VALEO PHARMA OBTAINS LISTINGS FOR REDESCA FROM TWO GPO REPRESENTING 700 HOSPITALS AND HEALTHCARE FACILITIES ACROSS CANADA 2 Group Purchasing Organizations (GPO) listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products The 2 multi-year product listings commenced on October 1, 2021 The GPOs together represent more than 700 hospitals […]
VALEO PHARMA COMPLETES NEGOTIATIONS WITH PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® Agreement to provide framework to participating jurisdictions in support of provincial public listings and reimbursements of both drugs Private payer health plan coverage exceeds 85% across Canada Scientific community demonstrates growing interest in both products MONTREAL, QUEBEC , October 5, 2021 […]
See all News →